Why did Abl­ynx board chair­man Pe­ter Fell­ner re­sign in wake of Novo's buy­out of­fer?; Am­gen vet Richard Paul­son tapped to run Ipsen North Amer­i­ca

→ What’s hap­pen­ing at Abl­ynx? On the same day Dan­ish bio­phar­ma No­vo Nordisk $NVO went pub­lic with its lat­est, $3.1 bil­lion of­fer to buy Abl­ynx $ABLX, the Bel­gian biotech an­nounced that Pe­ter Fell­ner has de­cid­ed to re­sign from its board. That abrupt de­par­ture trig­gered a lot of buzz that the un­usu­al over­ture from No­vo — not the kind of com­pa­ny you might typ­i­cal­ly find muscling a buy­out — has trig­gered some dis­sen­sion in the board. A for­mer mem­ber of the ad­vi­so­ry group to No­vo Nordisk Foun­da­tion’s in­vest­ing arm, Fell­ner has been on mul­ti­ple cor­po­rate boards. Bo Jes­per Hansen, a non-ex­ec­u­tive di­rec­tor and ex-CEO of Swedish Or­phan In­ter­na­tion­al, re­placed him as chair­man.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.